当前位置: X-MOL 学术Ann. Allergy Asthma Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Recent development on the use of sublingual immunotherapy tablets for allergic rhinitis
Annals of Allergy, Asthma & Immunology ( IF 5.9 ) Pub Date : 2021-05-23 , DOI: 10.1016/j.anai.2021.05.020
Susan Waserman 1 , Anita Shah 1 , Ernie Avilla 1
Affiliation  

Objective

Allergic rhinitis (AR) is an immunoglobulin (Ig) E–mediated inflammatory condition that causes sneezing, nasal congestion, rhinorrhea, and nasal itch. Although subcutaneous immunotherapy for the treatment of AR has been in use and well established as a treatment modality, sublingual immunotherapy (SLIT) is increasingly considered to be the safer and more convenient alternative. Thus, the objective of this review is to describe recent findings pertaining to the use of SLIT tablets (SLIT-T) for AR.

Data Sources

A database search (PubMed.gov) for articles published between January 1, 2017, and February 9, 2021, was conducted using the following key words: “allergic rhinitis,” AND-ed “sublingual immunotherapy.” Included were randomized placebo-controlled trials. Other experimental design studies were excluded.

Study Selections

A total of 11 randomized placebo-controlled trials were selected for full-text review and included in the analysis. All studies investigated the use of SLIT on patients with seasonal AR (4 tree pollen, 1 grass pollen, and 1 Japanese cedar) or perennial AR (3 house dust mite).

Results

Our review of 7 recently published randomized placebo-controlled trials with 2348 subjects receiving SLIT reported increased efficacy, safety, supportive immunologic parameters (IgE and IgG4 pre- and posttreatment levels), and improved quality of life. All studies excluded subjects with overlapping seasonal or perennial allergens, a history of moderate-to-severe uncontrolled asthma, or reduced lung function.

Conclusion

Our review highlights that SLIT is a safe and effective treatment that considerably reduces symptoms and medication requirements in AR and improves quality of life.



中文翻译:

舌下免疫治疗片治疗过敏性鼻炎的新进展

客观的

过敏性鼻炎 (AR) 是一种免疫球蛋白 (Ig) E 介导的炎症,可导致打喷嚏、鼻塞、流鼻涕和鼻痒。尽管用于治疗 AR 的皮下免疫疗法已被使用并作为一种治疗方式得到很好的确立,但越来越多地认为舌下免疫疗法 (SLIT) 是更安全、更方便的替代方案。因此,本综述的目的是描述有关使用 SLIT 片剂 (SLIT-T) 治疗 AR 的最新发现。

数据源

使用以下关键词对 2017 年 1 月 1 日至 2021 年 2 月 9 日期间发表的文章进行了数据库搜索 (PubMed.gov):“过敏性鼻炎”、AND-ed“舌下免疫疗法”。包括随机安慰剂对照试验。其他实验设计研究被排除在外。

研究选择

总共选择了 11 项随机安慰剂对照试验进行全文审查并纳入分析。所有研究都调查了 SLIT 在季节性 AR(4 种树花粉、1 种草花粉和 1 种日本雪松)或多年生 AR(3 种屋尘螨)患者身上的使用情况。

结果

我们对最近发表的 7 项随机安慰剂对照试验进行了回顾,其中 2348 名接受 SLIT 的受试者报告了疗效、安全性、支持性免疫参数(治疗前和治疗后的 IgE 和 IgG4 水平)以及生活质量的提高。所有研究都排除了季节性或常年性过敏原重叠、有中度至重度未控制哮喘病史或肺功能降低的受试者。

结论

我们的评论强调,SLIT 是一种安全有效的治疗方法,可显着减少 AR 的症状和药物需求,并提高生活质量。

更新日期:2021-05-23
down
wechat
bug